GlassScriptPhysician profile
Alexandra Samadi
NPI 1992401079
$2,805.48
in general payments reported to CMS, 2019-2025
20 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $500 · 2024: $825 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,613 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,612.93 |
| Education | $192.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $586.38 | 2024-2025 | Nucala, Trelegy Ellipta |
| Genzyme Corporation | $379.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $254.10 | 2023-2024 | Xifaxan, Trulance |
| Opko Pharmaceuticals, LLC | $192.55 | 2023-2025 | Rayaldee |
| Bausch & Lomb Americas INC. | $186.14 | 2025 | Vyzulta, Xiidra, Miebo |
| Amgen INC. | $175.60 | 2024 | Tepezza, Krystexxa |
| Ardelyx, INC. | $142.82 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $139.95 | 2023-2025 | Dupixent |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $107.82 | 2024-2025 | |
| Optinose US, INC. | $97.67 | 2025 | |
| Alcon Vision LLC | $75.69 | 2024-2025 | Rocklatan |
| Mallinckrodt Hospital Products INC. | $58.84 | 2025 | Acthar |
| Abbvie INC. | $50.50 | 2023-2024 | |
| Lilly USA, LLC | $49.78 | 2023-2024 | Jardiance |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.53 | 2023-2024 | Jardiance |
| Thea Pharma INC. | $45.18 | 2024 | Iyuzeh |
| Hikma Pharmaceuticals USA | $38.04 | 2023-2024 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $29.69 | 2025 | Xhance |
| Aimmune Therapeutics, INC. | $22.67 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Samadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.